BET bromodomain inhibition suppresses transcriptional responses to cytokine-Jak-STAT signaling in a gene-specific manner in human monocytes

European Journal of Immunology

Volumn 45, Issue 1, 2015, Pages 287-297

  Chan, Chun Hin ^a   Fang, Celestia ^a   Qiao, Yu ^a   Yarilina, Anna ^a   Prinjha, Rab K ^b   Ivashkiv, Lionel B ^a,c  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

^c Weill Cornell Medical Center   (United States)

Author keywords

Chromatin remodeling; Cytokines; Inflammation; Monocytes; Transcription

Indexed keywords

7 (3,5 DIMETHYL 4 ISOXAZOLYL) 1,3 DIHYDRO 8 METHOXY 1 [1 (2 PYRIDINYL)ETHYL] 2H IMIDAZO[4,5 C]QUINOLIN 2 ONE; BETA INTERFERON; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; JANUS KINASE; MYC PROTEIN; STAT PROTEIN; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR T BET; TUMOR NECROSIS FACTOR; CXCL10 PROTEIN, HUMAN; FUSED HETEROCYCLIC RINGS; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IL10 PROTEIN, HUMAN; IL4 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

ARTICLE; CELL POLARITY; CELL STIMULATION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOMODULATION; INFLAMMATION; MACROPHAGE; MONOCYTE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; ANTAGONISTS AND INHIBITORS; CELL DIFFERENTIATION; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; PHOSPHORYLATION; PRIMARY CELL CULTURE;

CELL DIFFERENTIATION; CHEMOKINE CXCL10; GENE EXPRESSION REGULATION; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; INTERFERON-BETA; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-4; JANUS KINASES; MACROPHAGES; MONOCYTES; PHOSPHORYLATION; PRIMARY CELL CULTURE; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS;

EID: 84921060280     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201444862     Document Type: Article

References (61)

1. Lawrence, T. and Natoli, G., Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nat. Rev. Immunol. 2011. 11: 750-761.
2. Ivashkiv, L. B., Epigenetic regulation of macrophage polarization and function. Trends Immunol. 2013. 34: 216-223.
3. Yarilina, A., Park-Min, K. H., Antoniv, T., Hu, X. and Ivashkiv, L. B., TNF activates an IRF1-dependent autocrine loop leading to sustained expression of chemokines and STAT1-dependent type I interferon-response genes. Nat. Immunol. 2008. 9: 378-387.
4. Gordon, S., Alternative activation of macrophages. Nat. Rev. Immunol. 2003. 3: 23-35.
5. Murray, P. J. and Wynn, T. A., Protective and pathogenic functions of macrophage subsets. Nat. Rev. Immunol. 2011. 11: 723-737.
6. Murray, P. J. and Wynn, T. A., Obstacles and opportunities for understanding macrophage polarization. J. Leukoc. Biol. 2011. 89: 557-563.
7. Mosser, D. M. and Edwards, J. P., Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 2008. 8: 958-969.
8. Chawla, A., Nguyen, K. D. and Goh, Y. P., Macrophage-mediated inflammation in metabolic disease. Nat. Rev. Immunol. 2011. 11: 738-749.
9. Deane, S., Selmi, C., Teuber, S. S. and Gershwin, M. E., Macrophage activation syndrome in autoimmune disease. Int. Arch. Allergy Immunol. 2010. 153: 109-120.
10. Moradinejad, M. H. and Ziaee, V., The incidence of macrophage activation syndrome in children with rheumatic disorders. Minerva Pediatr. 2011. 63: 459-466.
11. Hendriks, J. J., Teunissen, C. E., de Vries, H. E. and Dijkstra, C. D., Macrophages and neurodegeneration. Brain Res. Brain Res. Rev. 2005. 48: 185-195.
12. Moore, K. J., Sheedy, F. J. and Fisher, E. A., Macrophages in atherosclerosis: a dynamic balance. Nat. Rev. Immunol. 2013. 13: 709-721.
13. Espinoza-Jimenez, A., Peon, A. N. and Terrazas, L. I., Alternatively activated macrophages in types 1 and 2 diabetes. Mediators Inflamm. 2012. 2012: 815953.
14. Ruffell, B., Affara, N. I. and Coussens, L. M., Differential macrophage programming in the tumor microenvironment. Trends Immunol. 2012. 33: 119-126.
15. Doedens, A. L., Stockmann, C., Rubinstein, M. P., Liao, D., Zhang, N., DeNardo, D. G., Coussens, L. M. et al., Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. Cancer Res. 2010. 70: 7465-7475.
16. Lin, E. Y., Li, J. F., Gnatovskiy, L., Deng, Y., Zhu, L., Grzesik, D. A., Qian, H. et al., Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res. 2006. 66: 11238-11246.
17. Schmidt, T. and Carmeliet, P., Blood-vessel formation: bridges that guide and unite. Nature 2010. 465: 697-699.
18. Murdoch, C., Muthana, M., Coffelt, S. B. and Lewis, C. E., The role of myeloid cells in the promotion of tumour angiogenesis. Nat. Rev. Cancer 2008. 8: 618-631.
19. Natoli, G., Control of NF-kappaB-dependent transcriptional responses by chromatin organization. Cold Spring Harb. Perspect. Biol. 2009. 1: a000224.
20. Pham, T. H., Benner, C., Lichtinger, M., Schwarzfischer, L., Hu, Y., Andreesen, R., Chen, W. et al., Dynamic epigenetic enhancer signatures reveal key transcription factors associated with monocytic differentiation states. Blood 2012. 119: e161-e171.
21. Qiao, Y., Giannopoulou, E. G., Chan, C. H., Park, S. H., Gong, S., Chen, J., Hu, X. et al., Synergistic activation of inflammatory cytokine genes by interferon-gamma-induced chromatin remodeling and toll-like receptor signaling. Immunity 2013. 39: 454-469.
22. Ostuni, R., Piccolo, V., Barozzi, I., Polletti, S., Termanini, A., Bonifacio, S., Curina, A. et al., Latent enhancers activated by stimulation in differentiated cells. Cell 2013. 152: 157-171.
23. Vahedi, G., Takahashi, H., Nakayamada, S., Sun, H. W., Sartorelli, V., Kanno, Y. and O'Shea, J. J., STATs shape the active enhancer landscape of T cell populations. Cell 2012. 151: 981-993.
24. Smale, S. T., Selective transcription in response to an inflammatory stimulus. Cell 2010. 140: 833-844.
25. Ramirez-Carrozzi, V. R., Nazarian, A. A., Li, C. C., Gore, S. L., Sridharan, R., Imbalzano, A. N. and Smale, S. T., Selective and antagonistic functions of SWI/SNF and Mi-2beta nucleosome remodeling complexes during an inflammatory response. Genes Dev. 2006. 20: 282-296.
26. Egger, G., Liang, G., Aparicio, A. and Jones, P. A., Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004. 429: 457-463.
27. Hendrich, B. and Bickmore, W., Human diseases with underlying defects in chromatin structure and modification. Hum. Mol. Genet. 2001. 10: 2233-2242.
28. Bolden, J. E., Peart, M. J. and Johnstone, R. W., Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 2006. 5: 769-784.
29. Cheray, M., Pacaud, R., Nadaradjane, A., Vallette, F. M. and Cartron, P. F., Specific inhibition of one DNMT1-including complex influences tumor initiation and progression. Clin. Epigenetics 2013. 5: 9-15.
30. Qi, W., Chan, H., Teng, L., Li, L., Chuai, S., Zhang, R., Zeng, J. et al., Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc. Natl. Acad. Sci. USA 2012. 109: 21360-21365.
31. Dawson, M. A., Prinjha, R. K., Dittmann, A., Giotopoulos, G., Bantscheff, M., Chan, W. I., Robson, S. C. et al., Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2011. 478: 529-533.
32. Nicodeme, E., Jeffrey, K. L., Schaefer, U., Beinke, S., Dewell, S., Chung, C. W., Chandwani, R. et al., Suppression of inflammation by a synthetic histone mimic. Nature 2010. 468: 1119-1123.
33. Yang, Z., Yik, J. H., Chen, R., He, N., Jang, M. K., Ozato, K. and Zhou, Q., Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol. Cell. 2005. 19: 535-545.
34. Bres, V., Yoh, S. M. and Jones, K. A., The multi-tasking P-TEFb complex. Curr. Opin. Cell Biol. 2008. 20: 334-340.
35. Liu, W., Ma, Q., Wong, K., Li, W., Ohgi, K., Zhang, J., Aggarwal, A. K. et al., Brd4 and JMJD6-associated anti-pause enhancers in regulation of transcriptional pause release. Cell 2013. 155: 1581-1595.
36. Anders, L., Guenther, M. G., Qi, J., Fan, Z. P., Marineau, J. J., Rahl, P. B., Loven, J. et al., Genome-wide localization of small molecules. Nat. Biotechnol. 2014. 32: 92-96.
37. Heintzman, N. D., Hon, G. C., Hawkins, R. D., Kheradpour, P., Stark, A., Harp, L. F., Ye, Z. et al., Histone modifications at human enhancers reflect global cell-type-specific gene expression. Nature 2009. 459: 108-112.
38. Yanez-Cuna, J. O., Arnold, C. D., Stampfel, G., Boryn, L. M., Gerlach, D., Rath, M. and Stark, A., Dissection of thousands of cell type-specific enhancers identifies dinucleotide repeat motifs as general enhancer features. Genome Res. 2014. 7: 1147-1156.
39. Ernst, J., Kheradpour, P., Mikkelsen, T. S., Shoresh, N., Ward, L. D., Epstein, C. B., Zhang, X. et al., Mapping and analysis of chromatin state dynamics in nine human cell types. Nature 2011. 473: 43-49.
40. Mertz, J. A., Conery, A. R., Bryant, B. M., Sandy, P., Balasubramanian, S., Mele, D. A., Bergeron, L. et al., Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc. Natl. Acad. Sci. USA 2011. 108: 16669-16674.
41. Delmore, J. E., Issa, G. C., Lemieux, M. E., Rahl, P. B., Shi, J., Jacobs, H. M., Kastritis, E. et al., BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011. 146: 904-917.
42. Ott, C. J., Kopp, N., Bird, L., Paranal, R. M., Qi, J., Bowman, T., Rodig, S. J. et al., BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood 2012. 120: 2843-2852.
43. Delmore, J. E., Issa, G. C., Lemieux, M. E., Rahl, P. B., Shi, J., Jacobs, H. M. D., Kastritis, E. et al., BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011. 146: 904-917.
44. Huang, B., Yang, X. D., Zhou, M. M., Ozato, K. and Chen, L. F., Brd4 coactivates transcriptional activation of NF-kappaB via specific binding to acetylated RelA. Mol. Cell. Biol. 2009. 29: 1375-1387.
45. Decker, T., Muller, M. and Stockinger, S., The yin and yang of type I interferon activity in bacterial infection. Nat. Rev. Immunol. 2005. 5: 675-687.
46. Young, H. A. and Bream, J. H., IFN-gamma: recent advances in understanding regulation of expression, biological functions, and clinical applications. Curr. Top. Microbiol. Immunol. 2007. 316: 97-117.
47. Begitt, A., Droescher, M., Meyer, T., Schmid, C. D., Baker, M., Antunes, F., Owen, M. R. et al., STAT1-cooperative DNA binding distinguishes type 1 from type 2 interferon signaling. Nat. Immunol. 2014. 15: 168-176.
48. Pello, O. M., De Pizzol, M., Mirolo, M., Soucek, L., Zammataro, L., Amabile, A., Doni, A. et al., Role of c-MYC in alternative activation of human macrophages and tumor-associated macrophage biology. Blood 2012. 119: 411-421.
49. Loven, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. et al., Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 2013. 153: 320-334.
50. Muller, S., Filippakopoulos, P. and Knapp, S., Bromodomains as therapeutic targets. Expert Rev. Mol. Med. 2011. 13: e29-e50.
51. Yellin, M., Paliienko, I., Balanescu, A., Ter-Vartanian, S., Tseluyko, V., Xu, L. A., Tao, X. et al., A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 2012. 64: 1730-1739.
52. Mayer, L., Sandborn, W. J., Stepanov, Y., Geboes, K., Hardi, R., Yellin, M., Tao, X. et al., Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. Gut 2013. 63: 442-450.
53. Patel, M. C., Debrosse, M., Smith, M., Dey, A., Huynh, W., Sarai, N., Heightman, T. D. et al., BRD4 coordinates recruitment of pause release factor P-TEFb and the pausing complex NELF/DSIF to regulate transcription elongation of interferon-stimulated genes. Mol. Cell Biol. 2013. 33: 2497-2507.
54. Hargreaves, D. C., Horng, T. and Medzhitov, R., Control of inducible gene expression by signal-dependent transcriptional elongation. Cell 2009. 138: 129-145.
55. Denis, G. V., Bromodomain coactivators in cancer, obesity, type 2 diabetes, and inflammation. Discov. Med. 2010. 10: 489-499.
56. Ivashkiv, L. B. and Donlin, L. T., Regulation of type I interferon responses. Nat. Rev. Immunol. 2014. 14: 36-49.
57. Shuai, K. and Liu, B., Regulation of JAK-STAT signalling in the immune system. Nat. Rev. Immunol. 2003. 3: 900-911.
58. Au-Yeung, N., Mandhana, R. and Horvath, C. M., Transcriptional regulation by STAT1 and STAT2 in the interferon JAK-STAT pathway. JAKSTAT 2013. 2: e23931.
59. Rahman, S., Sowa, M. E., Ottinger, M., Smith, J. A., Shi, Y., Harper, J. W. and Howley, P. M., The Brd4 extraterminal domain confers transcription activation independent of pTEFb by recruiting multiple proteins, including NSD3. Mol. Cell Biol. 2011. 31: 2641-2652.
60. van Meerloo, J., Kaspers, G. J. and Cloos, J., Cell sensitivity assays: the MTT assay. Methods Mol. Biol. 2011. 731: 237-245.
61. Hu, X., Herrero, C., Li, W. P., Antoniv, T. T., Falck-Pedersen, E., Koch, A. E., Woods, J. M. et al., Sensitization of IFN-gamma Jak-STAT signaling during macrophage activation. Nat. Immunol. 2002. 3: 859-866.